Shionogi & Co Ltd Executive and Leadership Team

Takeshi Kasuya, the Chief Executive Officer at Shionogi & Co Ltd, directs the overarching corporate strategy and operational execution. Kasuya guides the company's mission to develop innovative treatments that significantly improve patient lives globally. This leadership involves setting the strategic direction for research and development, ensuring alignment with pressing global health challenges, particularly in infectious diseases. Kasuya oversees the integration of in-house discovery efforts with external collaborations, fostering partnerships with industry, government, and academia to accelerate therapeutic advancements. The Chief Executive Officer's role is critical in driving the company's commitment to delivering novel therapies for conditions such as antibiotics, HIV, influenza, and emerging viral threats with urgency and precision. By championing a culture of scientific rigor and patient-centricity, Kasuya ensures Shionogi & Co Ltd maintains its pioneering status in pharmaceutical innovation.

Isao Teshirogi, the Representative Director, President & Chief Executive Officer at Shionogi & Co Ltd, spearheads the company's strategic vision and global operations. Teshirogi drives the core mission of developing groundbreaking treatments to enhance patient well-being worldwide, with a particular emphasis on addressing critical infectious disease challenges. This involves orchestrating the discovery and delivery of novel therapies, including antibiotics, HIV treatments, influenza medications, and solutions for emerging viral threats like COVID-19. The President & Chief Executive Officer fosters strategic alliances across industry, government, and academic sectors, accelerating the development pipeline. Isao Teshirogi ensures Shionogi & Co Ltd combines robust in-house R&D with external collaborations to bring vital therapies to market with speed and accuracy. This leadership role is fundamental to maintaining the company's pioneering legacy and its commitment to urgent, precise patient care on a global scale.

Masahiro Fujita, the Senior Vice President & Chief Financial Officer at Shionogi & Co Ltd, manages the company's financial health and strategic resource allocation. Fujita oversees all financial operations, including budgeting, forecasting, and investment strategies, ensuring fiscal responsibility across the organization. This role is crucial for supporting Shionogi & Co Ltd's dedication to developing innovative treatments for global health challenges. The Chief Financial Officer plays a key part in evaluating the financial viability of research and development programs, particularly those targeting infectious diseases like antibiotics, HIV, and emerging viral threats. Masahiro Fujita works closely with other executive leaders to secure funding for strategic collaborations with industry, government agencies, and academic institutions, thereby accelerating the advancement of scientific programs. By maintaining robust financial controls and strategic financial planning, Fujita enables the company to deliver meaningful therapies to patients with the required urgency and precision.

Tsutae Nagata, the Chief Medical Officer at Shionogi & Co Ltd, leads the clinical development and medical affairs strategy for the company's therapeutic pipeline. Nagata directs the execution of clinical trials and ensures adherence to the highest medical and ethical standards in the development of innovative treatments. This leadership is vital for Shionogi & Co Ltd's mission to address pressing global health challenges, especially in the realm of infectious diseases. The Chief Medical Officer oversees the medical strategy for novel therapies, including antibiotics, HIV, influenza, and emerging viral threats such as COVID-19. Tsutae Nagata collaborates closely with research and development teams and external partners, including academic institutions and regulatory bodies, to expedite the advancement of scientific programs. By guiding the clinical validation and medical positioning of new therapies, Nagata ensures Shionogi & Co Ltd can deliver urgent and precise medical solutions to patients worldwide.